Evidence map›Paper›PMID 37792614›Full record

ReviewThe New England journal of medicine2023

Stem-Cell Aging and Pathways to Precancer Evolution.

Catriona H M Jamieson, Irving L Weissman

Abstract readReview
In one paragraph

Review in The New England journal of medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed.

  1. T Cell Thoughts.Immunological reviews · 2026
    Review
  2. Review
  3. Signaling pathways and targeted interventions for precancers.Signal transduction and targeted therapy · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Fibroblasts in heterotopic ossification: mechanisms and therapeutic targets.International journal of biological sciences · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Catriona H M JamiesonFrom the Sanford Stem Cell Institute, Division of Regenerative Medicine, Department of Medicine, University of California at San Diego, La Jolla (C.H.M.J.), and the Institute for Stem Cell Biology and Regenerative Medicine, Stanford University Medical Center, Stanford (I.L.W.) - both in California.
Irving L WeissmanFrom the Sanford Stem Cell Institute, Division of Regenerative Medicine, Department of Medicine, University of California at San Diego, La Jolla (C.H.M.J.), and the Institute for Stem Cell Biology and Regenerative Medicine, Stanford University Medical Center, Stanford (I.L.W.) - both in California.

Funding

Stem Cell Biology, Cancer Stem Cell Biology, and Cancer ImmunotherapyR35CA220434 · NCI · STANFORD UNIVERSITY · PI WEISSMAN, IRVING L. · 2017 to 2023
$6.7M
NCI NIH HHS R35 CA220434
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AgingPrecancerous ConditionsStem CellsCellular SenescenceHumans

Identifiers

PMID37792614
PMCPMC11908798

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.